Swixx BioPharma replaces biopharma, OTC, and medical device multinationals' subsidiaries in countries or therapeutic areas that their partners choose not to enter or exit. Swixx BioPharma operates in Central & Eastern Europe, Russia/Eurasia, Greece, the Middle East, and Latin America, providing access to medical innovations from international healthcare companies.

Swixx BioPharma

Swixx BioPharma is designed to fully replace biopharma, OTC and medical device multinationals’ subsidiaries or business units in those countries, or therapeutic areas of CEE, that the multinational chooses not to enter, or to exit

Citi

Credit Suisse

HBM Healthcare Investments AG

Mérieux Equity Partners

🎉 We are thrilled to kick off the celebration of our 10-year anniversary! Ten years ago, we started our journey in Serbia with a small team of enthusiasts determined to make a difference. Since then, we've grown to a company with presence in CEE, Eurasia/CIS, MENA and LATAM, becoming a reliable partner in our communities, a trusted ally to healthcare providers, and a professional service provider to multinational companies.

To mark a first decade of hard work, dedication, and success, we are excited to unveil our updated logo featuring a special 10-year mark and the tagline: "Celebrating a First Decade of Improving Lives". Check out our new logo on our website and social media starting today and join us in celebrating this milestone of our tremendous journey!

#10Years #Anniversary #Swixx #PartnerforPharma

We are delighted to announce the appointment of Piret Tuul as our new Regional Baltic General Manager for Lithuania, Latvia, and Estonia. Piret brings over 28 years of experience in the pharmaceutical industry, including roles at Schering-Plough, Roche, Novartis, and Takeda. Her impressive career includes various positions in sales, marketing, regulatory, and business management, with increasing responsibilities and covered geographies and significant achievements in oncology, rare diseases, and other specialized therapies.
Piret Tuul's academic background includes a B.Sc. in Biology, an M.Sc. in Biochemistry, and an MBA in Marketing and Health Economy from Tartu University, Estonia. Her leadership and strategic skills have driven business growth, product launches, and successful integrations. We are convinced that her proven people management skills and industry and therapeutic area knowledge will reinforce the growth of our local organization.
Welcome to Swixx, Piret!

#Swixx #PartnerforPharma #newemployee #welcometotheteam

🌎 Important news from Swixx BioPharma  

We are delighted to announce the closing of the acquisition of Laboratorios Biopas, a leading marketing and distribution company for international biopharmaceutical firms in the Latin America. The combination with Laboratorios Biopas extends & transforms Swixx BioPharma's geographical footprint creating a compelling, single-stop, multi-continent partner for biopharma companies in Central and Eastern Europe, CIS/Eurasia, MENA and now Latin America. 

Jean-Michel Lespinasse, CEO of Swixx BioPharma, commented: “We are thrilled to welcome Biopas into the Swixx BioPharma family. Building on our matching cultures and vision, the combined entity firmly moves forward, leveraging its global strengths and capabilities to better serve the needs of patients and healthcare professionals.” 

You can access the full Press release on our website here: https://lnkd.in/d6szV3Hv 

#Swixx #PartnerforPharma #BusinessExpansion #Biopas

🚀 Exciting News from Swixx BioPharma 🌎

We are thrilled to announce our strategic expansion into Latin America with the signature of an agreement to acquire the equity of Pharma Consulting Group S.A., the holding company of Laboratorios Biopas, a leading marketing and distribution company for international biopharmaceutical firms in the region. Through Laboratorios Biopas’ comprehensive Latam continental coverage, Swixx BioPharma will now be able to provide a compelling, single-stop, multi-continent solution for biopharma companies with the coverage of Central and Eastern Europe, CIS/Eurasia, MENA and now Latin America. 🌍💊
The transaction is set to close between June and July 2024. 

With over 1,300 employees and being recognized by the Financial Times as one of Europe’s fastest growing companies in 2024, the expansion marks another important step towards fulfilling Swixx BioPharma’s mission to become the preferred partner for biopharma companies seeking indirect routes to launch and commercialize their medicines. 

🤝 We are committed to seamless business continuity, therefore the Biopas leadership team remains at the helm of the combined company in Latam and Biopas name is retained for Latam operations.

You can access the full Press release on our website here: https://lnkd.in/dRan-qPC

#Swixx #PartnerforPharma #BusinessExpansion

At Swixx BioPharma, we join the global community in raising awareness about the life-saving impact of vaccines. 
Georgi, our Medical Lead Vaccines, reflects on the importance of vaccination for our communities.

#HumanlyPossible #WorldImmunizationWeek #Swixx #Partnerforpharma

🌍✨ As proud partner of Sanofi, Swixx BioPharma is joining global community efforts in raising awareness about the profound impact of vaccines on public health during 2024 World Immunization Week.
According to the World Health Organization, vaccines are one of humanity’s greatest achievements. WHO pledge Humanly Possible outlines the need to expand access and funding of vaccination across the world so that everyone can benefit from the life-saving power of vaccines. By ensuring widespread access to vaccines, we can build healthier and more resilient societies. 

#HumanlyPossible #WorldImmunizationWeek #Swixx #Partnerforpharma

We are delighted to announce that Michal Koutny, FCCA joins Swixx BioPharma as Executive Director Finance.
Michal holds a master’s degree from Technical University of Ostrava, the Czech Republic, and is certified accountant from the United Kingdom. Michal joins us from Ipsen where he held positions of Finance Director Germany/Austria/Switzerland, Head of Finance of International Clusters/China, and Head of Finance Europe. Prior to Ipsen, Michal worked for 14 years in BMS within Financial Analysis country and regional teams, as Finance Director in Greece/Cyprus, and as Senior Finance Director with responsibility over LATAM, South East Asia and Intercontinental HQ. 
With his rich experience, proven track record, and people-oriented management style, Michal is set to drive excellence and innovation within the finance function in Swixx, thus supporting our company growth and expansion.
Welcome Michal to Swixx!

#Swixx #PartnerforPharma #newemployee #welcometotheteam

📢 Important announcement!

Swixx BioPharma proudly announces it has been recognized as one of Europe’s Fastest-Growing Companies by the Financial Times newspaper. The latest FT/Statista ranking of Europe’s fastest-growing companies has included Swixx Biopharma in the well-known FT1000 list. Swixx BioPharma ranked 9th in the Health Care & Life Sciences sector with a 70,6% Compound Annual Growth Rate (CAGR) 2019-2022.

Swixx’s CEO, Jean-Michel Lespinasse, enthused that being featured “in the FT1000 list marks a significant, objective recognition of the extraordinary growth Swixx has enjoyed in the last years. This acknowledgment reaffirms our vision to become the No. 1 Commercial platform not only in CEE, but beyond – into other markets where our partners consider that Swixx can be of service…. My sincere congratulations go to each member of our Swixx team. I thank them for their dedication, passion, and commitment to excellence, which have provided the driving force to power our growth."

Read the full announcement on the link: https://lnkd.in/gvgFwV_V 

#Swixx #Partnerforpharma #FT1000

On this Rare Disease Day, we are honored to share the remarkable journey of a family touched by Pompe Disease. Meet Dragana and Vanja, aunt and niece, whose resilience and love epitomize the strength within the rare disease community. 
Pompe Disease, affecting approximately 1 in 100,000 individuals in the EU, presents profound challenges such as muscle weakness, respiratory difficulties, and heart complications. Through their courage and determination, Dragana and Vanja remind us of the importance of unity and support in the face of adversity. 
As we celebrate Rare Disease Day, let's stand together, listen to their stories, and advocate passionately for improved care and resources for all those affected by Pompe Disease. Together, we can ignite hope and foster a future of compassion and understanding.

#Swixx #Partnerforpharma #rarediseaseday2024 #HealthEquity

According to EURORDIS-Rare Diseases Europe, rare diseases collectively impact 30 million people in the EU. Every rare disease story is unique, but it always pictures immense strength and perseverance. 
As we mark #rarediseaseday, we acknowledge the need for an equitable access to care and treatment options for all individuals living with rare diseases, regardless of where they live, as well as the importance of partnerships with the patient community.

#Swixx #Partnerforpharma #rarediseaseday2024 #HealthEquity

IPhone / Mobile Compatible

Viewport Meta

Google Tag Manager

Apple Mobile Web Clips Icon

Euro

Google Analytics

Global Site Tag

nginx

Google Analytics 4

Google Universal Analytics

Business Management

Cristina Pentiuc

Finance Director

Kristina Manhard

HR and Administrative Director, Russia and Eurasia

Maria Sinyakova

Director Supply Chain Operations Russia and Eurasia

Oleg Markov

Sales and Support

Pavel Chistyakov

Bussines Unit Head Rare Diseases

Petra Stefankova

Healthcare

Valentin Dudau

Vladimir Dumler

Head of Business Operations and Strategy

Alexander Lyskovets

Finance Manager Romania

Alexandru Razicheanu

Benoit Chastaing

Stuart Swanson

Petr Nemec

Co-Founder

Marcela Lassakova

Chief Compliance Officer

Jean-Michel Lespinasse

Petr Pipal

Dezso Martha

COO & Head of Rare Diseases BU and Alliance Management

Europe Companies With More Than $10M in Revenue (Top 10K)

Companies With More Than $50M in Revenue (Top 10K)

Private Zug Companies

Mérieux Equity Partners Portfolio Companies

Swixx Biopharma fully represents biopharma companies in the CEE. It is designed to fully replace biopharma, OTC, and medical device multinationals’ subsidiaries or business units in those countries, or therapeutic areas of CEE, that the multinational chooses not to enter, or to exit.

The company was founded in 2014 and is registered in Baar, Switzerland. It has 100%-owned affiliates in Albania, Bosnia & Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Greece, Hungary, Kosovo, Latvia, Lithuania, North Macedonia, Montenegro, Poland, Romania, Russia, Serbia, Slovakia, and Slovenia.

Venture Round - Swixx Biopharma

Debt Financing - Swixx Biopharma

Baar

Switzerland

Europe

Swixx Biopharma

Swixx BioPharma acquires Biopoas

SWIXX BIOPHARMA EXPANDS TO LATIN AMERICA THROUGH A STRATEGIC ACQUISITION AND COMBINATION ...

SWIXX BIOPHARMA SE EXPANDE A LATINOAMÉRICA AL UNIRSE A BIOPAS CON UNA ADQUISICIÓN ESTRATÉGICA

SWIXX BIOPHARMA EXPANDS TO LATIN AMERICA THROUGH A STRATEGIC ACQUISITION AND COMBINATION WITH BIOPAS

SWIXX BIOPHARMA S'ÉTEND EN AMÉRIQUE LATINE GRÂCE À UNE FUSION-ACQUISITION STRATÉGIQUE AVEC BIOPAS

SWIXX BIOPHARMA EXPANDIERT NACH LATEINAMERIKA DURCH STRATEGISCHE AKQUISITION UND ZUSAMMENSCHLUSS MIT BIOPAS

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general
public peers	general	Aug 23, 2024 11:47 PM	fe3c32ff
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
news advanced	general
news impact assignment advanced	general
signals	general
news processing advanced	general
crunchbase trigger	general	Oct 28, 2024 1:51 PM	e6b8d5f4
crunchbase profile	general	Oct 28, 2024 3:45 PM	22e88805
li profile	general	Aug 23, 2024 11:47 PM	3e5fd240
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	7f484837
peers	general	Aug 23, 2024 11:47 PM	5c012a2b
news basic	general	Aug 23, 2024 11:47 PM	5db7441c
events	markdown
bundesanzeiger	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis
funding rounds analysis	company_analysis
company structure	company_analysis
purchaser profile	merger_acquisitions
private financials	financials
customer profile	customers

SWIX

COM:SWIXXBIOPHARMA

Swixx BioPharma